BlackRock, Inc. (NAGE) discloses 5.2% beneficial stake in Niagen Bioscience common stock
BlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 4,161,626 shares of Niagen Bioscience, Inc. common stock, or 5.2% of the class, as of a signature date of July 29, 2026. The filing shows sole voting power of 4,097,677 shares and sole dispositive power of 4,161,626 shares.
How this was made
The 30-second read
Why it matters
The key new information is BlackRock’s disclosed 5.2% beneficial ownership in NAGE, which may influence investor positioning and ownership sentiment but does not, by itself, change company fundamentals.
Market read
Ownership disclosures can affect flows and sentiment, but this text contains no operational catalyst beyond the stake size.
What to watch
Traders may overreact to the 5% threshold; the filing also states no single underlying person exceeds 5%, and it does not indicate activism, board changes, or a planned transaction.
Background
The filing is a Schedule 13G, which investors use to report beneficial ownership of significant stakes, typically without seeking control.
Ticker impact
BlackRock filed a Schedule 13G showing 4,161,626 shares, or 5.2% beneficial ownership, in Niagen Bioscience common stock.
Near-term price impact is likely limited, but the disclosure can support incremental bid from investors tracking institutional ownership.
The article provides a primary-source ownership disclosure (Schedule 13G) with exact share count and percent of class, but no accompanying intent (control, activism) or operational catalyst.
Market effects
Institutional ownership updates can marginally affect sentiment toward small-cap biotech, but no sector-wide signal is provided.
No specific regional market linkage is described.
No global macro or cross-border transaction details are included.
Counterpoint
A Schedule 13G often reflects passive or investment intent, so the stake may not translate into near-term fundamental change for NAGE.
Key entities
- institutional investorBlackRock, Inc.
Filed the Schedule 13G reporting beneficial ownership of Niagen Bioscience common stock.
- issuerNiagen Bioscience, Inc.
The company whose common stock is subject of the reported 5.2% beneficial stake.
